CRISPR Therapeutics (CRSP) News Today $37.84 -1.41 (-3.60%) As of 01:20 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Why is CRISPR Therapeutics Down Today?CRISPR Therapeutics AG (NASDAQ: CRSP) shares have traded higher, supported by a wave of bullish analyst notes and a major strategic partnership. Analyst Reaffirmations JMP Securities reaffirmed its “Market Outperform” rating and boosted the price target to $86.00, implying more than 120% upside. Needham & Company maintained a “Buy” rating with an $81.00 target, while HC Wainwright reiterated its “Buy” stance and a $65.00 target. $95M Sirius Therapeutics Collaboration CRSP agreed to pay up to $95 million upfront to partner with Sirius Therapeutics on siRNA drug candidates targeting blood‐clotting disorders. This deal marks a strategic expansion beyond permanent gene editing into reversible gene silencing, diversifying CRISPR’s pipeline and potentially mitigating regulatory and safety hurdles. Positive Media Coverage The Motley Fool highlighted CRSP as a potential high‐growth Opportunity, noting existing FDA approval and a valuation seen as overly discounted. Investors are bullish on CRISPR’s broadened therapeutic approach and the strong upside signaled by multiple price targets, driving buying interest in the stock.Posted 22m agoAI generated CRSP Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period CRISPR Therapeutics AG (CRSP) Strikes $95M Deal with Sirius to Develop Blood Clot DrugMay 21 at 12:25 AM | insidermonkey.comCRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Rafferty Asset Management LLCRafferty Asset Management LLC trimmed its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 22.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 165,816 shares of the company's stock afMay 20 at 5:38 AM | marketbeat.comCRISPR Therapeutics Stock Could Double Your Money, According to Wall Street. Is It Time to Buy?May 20 at 5:11 AM | fool.com5 Monster Stocks to Hold for the Next 10 YearsMay 20 at 4:30 AM | fool.comNorthern Trust Corp Increases Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)Northern Trust Corp increased its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 12.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 257,168 shares of the company's stock after buying an addiMay 20 at 3:31 AM | marketbeat.comCrispr Therapeutics to Partner With Sirius Therapeutics to Develop siRNA TherapiesMay 20 at 2:15 AM | marketwatch.comCRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA TherapiesMay 20 at 2:15 AM | finance.yahoo.comCRISPR Therapeutics AG (CRSP) Announces Strategic Partnership with Sirius Therapeutics | CRSP ...May 19 at 5:25 PM | gurufocus.comCrispr Therapeutics AG Partners with Sirius on siRNA TechMay 19 at 5:25 PM | tipranks.comLazard Asset Management LLC Decreases Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)Lazard Asset Management LLC decreased its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 16.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 71,023 shareMay 19 at 4:43 AM | marketbeat.comPrediction: This Beaten-Down Stock Could Double in The Next 5 YearsMay 18 at 9:30 AM | fool.comBank of America Corp DE Grows Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)Bank of America Corp DE boosted its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 12.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,211,509 shares of the company's stock after buying an additiMay 17, 2025 | marketbeat.comCRSPR Stock Could Be Ready to Deliver on Its Massive PromiseCRSPR Therapeutics has ambitious goals for its gene editing technology and may be getting ready to generate the revenue needed to deliver for shareholdersMay 16, 2025 | marketbeat.comCresset Asset Management LLC Sells 12,037 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)Cresset Asset Management LLC lessened its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 44.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,042 shares of the company's stoMay 16, 2025 | marketbeat.comAre Investors Making a Big Mistake Dumping Shares of CRISPR Therapeutics?May 15, 2025 | msn.comWhat is Chardan Capital's Forecast for CRSP FY2025 Earnings?May 13, 2025 | americanbankingnews.comChardan Capital Issues Optimistic Forecast for CRSP EarningsCRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Equities research analysts at Chardan Capital lifted their FY2025 EPS estimates for shares of CRISPR Therapeutics in a research report issued to clients and investors on Wednesday, May 7th. Chardan Capital analyst Y. Livshits now forecasts thatMay 13, 2025 | marketbeat.comQ2 EPS Estimate for CRISPR Therapeutics Raised by AnalystCRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Equities research analysts at HC Wainwright upped their Q2 2025 earnings per share estimates for shares of CRISPR Therapeutics in a research report issued to clients and investors on Wednesday, May 7th. HC Wainwright analyst M. Kapoor now anticMay 13, 2025 | marketbeat.comCRISPR Therapeutics (CRSP) Projected to Post Quarterly Earnings on WednesdayMay 13, 2025 | americanbankingnews.comCan Buying CRISPR Therapeutics and Holding It Forever Make You a Millionaire?May 12, 2025 | fool.comHC Wainwright Issues Optimistic Estimate for CRSP EarningsMay 12, 2025 | americanbankingnews.comCRISPR Therapeutics (NASDAQ:CRSP) Price Target Lowered to $42.00 at BarclaysBarclays lowered their price objective on shares of CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating for the company in a report on Friday.May 11, 2025 | marketbeat.comQ2 EPS Forecast for CRISPR Therapeutics Lowered by AnalystCRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Equities research analysts at Brookline Capital Management reduced their Q2 2025 earnings per share (EPS) estimates for shares of CRISPR Therapeutics in a report issued on Tuesday, May 6th. Brookline Capital Management analyst L. Cann now forecMay 11, 2025 | marketbeat.comLeerink Partnrs Issues Pessimistic Outlook for CRSP EarningsCRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Investment analysts at Leerink Partnrs cut their Q2 2025 EPS estimates for shares of CRISPR Therapeutics in a report issued on Tuesday, May 6th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings of ($1.45)May 11, 2025 | marketbeat.comWilliam Blair Expects Lower Earnings for CRISPR TherapeuticsCRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - William Blair decreased their Q2 2025 earnings per share estimates for shares of CRISPR Therapeutics in a report released on Wednesday, May 7th. William Blair analyst S. Corwin now expects that the company will post earnings per share of ($1.10May 11, 2025 | marketbeat.comCRSP FY2025 EPS Estimate Raised by Cantor FitzgeraldMay 11, 2025 | americanbankingnews.comQ2 EPS Forecast for CRISPR Therapeutics Decreased by AnalystMay 11, 2025 | americanbankingnews.comLeerink Partnrs Has Negative Outlook of CRSP Q2 EarningsMay 11, 2025 | americanbankingnews.com3 Monster Stocks to Hold for the Next 10 YearsMay 10, 2025 | fool.comBenjamin Edwards Inc. Acquires 12,359 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)Benjamin Edwards Inc. lifted its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 37.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,062 shares of the comMay 10, 2025 | marketbeat.comCRISPR Therapeutics (NasdaqGM:CRSP) Q1 2025 Revenue Increases 71% to US$1 MillionMay 9, 2025 | finance.yahoo.comNeedham & Company LLC Lowers CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $81.00Needham & Company LLC lowered their price target on CRISPR Therapeutics from $84.00 to $81.00 and set a "buy" rating on the stock in a research report on Wednesday.May 9, 2025 | marketbeat.comChardan Capital Cuts CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $82.00Chardan Capital reduced their target price on shares of CRISPR Therapeutics from $84.00 to $82.00 and set a "buy" rating for the company in a report on Wednesday.May 9, 2025 | marketbeat.comCrispr Therapeutics: Complex Casgevy Launch, But Broader Gene-Editing Potential Still ShinesMay 9, 2025 | seekingalpha.comCRISPR Therapeutics (CRSP) to Release Earnings on WednesdayCRISPR Therapeutics (NASDAQ:CRSP) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 14. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-14-crispr-therapeutics-ag-stock/)May 9, 2025 | marketbeat.comCRISPR Therapeutics Struggles Under Slow Adoption And Regulatory Uncertainty (Downgrade)May 8, 2025 | seekingalpha.comBeware of Sarepta, CRISPR Therapeutics, and MoreMay 8, 2025 | baystreet.caBridgefront Capital LLC Makes New Investment in CRISPR Therapeutics AG (NASDAQ:CRSP)Bridgefront Capital LLC purchased a new position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 17,264 shares of the company's stock, valued atMay 8, 2025 | marketbeat.comCathie Wood’s ARK ETFs buy AMD and CRISPR, sell Palantir stockMay 7, 2025 | investing.comCrispr Therapeutics Q1 Earnings Analysis: Ignore The Gloom, Stay The CourseMay 7, 2025 | seekingalpha.comCRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: AnalystMay 7, 2025 | benzinga.comWe're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn RateMay 7, 2025 | finance.yahoo.comThese Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 ResultsMay 7, 2025 | benzinga.comDimensional Fund Advisors LP Has $37.28 Million Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)Dimensional Fund Advisors LP boosted its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 14.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 947,301 shares of the company's stock after purchasingMay 7, 2025 | marketbeat.comCRISPR Therapeutics AG Reports Q1 2025 EPS of -$1.58 and Revenue of $865K, Missing EstimatesMay 6, 2025 | gurufocus.comCRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3May 6, 2025 | globenewswire.comCRISPR Therapeutics AG (NASDAQ:CRSP) Shares Purchased by Baker BROS. Advisors LPBaker BROS. Advisors LP grew its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 55.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,308,011 shares of the companyMay 6, 2025 | marketbeat.comCRISPR Therapeutics (CRSP) Short Sellers Have A Lot Riding on EarningsMay 5, 2025 | 247wallst.comCRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Rating of "Hold" from BrokeragesCRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) has been assigned a consensus rating of "Hold" from the twenty-one brokerages that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation anMay 4, 2025 | marketbeat.comCathie Wood Makes Surprising Moves by Buying AMD and Selling CRISPRMay 1, 2025 | theglobeandmail.com Get CRISPR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Email Address CRSP Media Mentions By Week CRSP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRSP News Sentiment▼0.720.65▲Average Medical News Sentiment CRSP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRSP Articles This Week▼1711▲CRSP Articles Average Week Get CRISPR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Exelixis News Neurocrine Biosciences News Moderna News Qiagen News Bio-Techne News Revolution Medicines News Repligen News Halozyme Therapeutics News ADMA Biologics News Vaxcyte News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRSP) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISPR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
